Cancer Research and Treatment

Current Landscape of Immunotherapy for Advanced Sarcoma

Víctor Albarrán, María Luisa Villamayor, Javier Pozas, Jesús Chamorro, Diana Isabel Rosero, María San Román, Patricia Guerrero, Patricia Pérez de Aguado, Juan Carlos Calvo, Coral García de Quevedo, Carlos González, María Ángeles Vaz

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Enrico Lucarelli, Alessandro De Vita, Chiara Bellotti, Tommaso Frisoni, Silvia Vanni, Ania Naila Guerrieri, Micaela Pannella, Laura Mercatali, Marco Gambarotti, Serena Duchi, Giacomo Miserocchi, Margherita Maioli, Chiara Liverani, Toni Ibrahim

PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas

Vasiliki Siozopoulou, Evelien Smits, Karen Zwaenepoel, Jimmy Liu, Abraham Pouliakis, Patrick A Pauwels, Elly Marcq

Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study

Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A. Gupta

Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef

Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives

Targeted therapies and checkpoint inhibitors in sarcoma

M Vasella, E Gousopoulos, M Guidi, G Storti, S Y Song, G Grieb, C Pauli, N Lindenblatt, P Giovanoli, B -S Kim

QJM: An International Journal of Medicine.2022; 115(12): 793. CrossRef

Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series

Arielle Elkrief, Suzanne Kazandjian, Thierry Alcindor

Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient

Yi Luo, Li Min, Yong Zhou, Fan Tang, Minxun Lu, Hongmei Xie, Yitian Wang, Hong Duan, Wenli Zhang, Chongqi Tu

Is immunotherapy in the future of therapeutic management of sarcomas?

Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano, Sabrina Lamia, Lucia Cannella, Antonio Pizzolorusso, Massimiliano Di Marzo, Mariachiara Santorsola, Annarosaria De Chiara, Flavio Fazioli, Salvatore Tafuto

Journal of Translational Medicine.2021;[Epub] CrossRef

Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I

Javier Martínez-Trufero, Josefina Cruz Jurado, M.Carmen Gómez-Mateo, Daniel Bernabeu, Luis Javier Floría, Javier Lavernia, Ana Sebio, Xavier García del Muro, Rosa Álvarez, Raquel Correa, C.Nieves Hernández-León, Gloria Marquina, Nadia Hindi, Andrés Redond

Cancer Treatment Reviews.2021; 99: 102259. CrossRef

Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report

Makoto Nakagawa, Eisuke Kobayashi, Masayoshi Yamada, Tomoko Watanabe, Makoto Hirata, Noriko Tanabe, Mineko Ushiama, Hiromi Sakamoto, Chiaki Sato, Taisuke Mori, Akihiko Yoshida, Teruhiko Yoshida, Kokichi Sugano, Akira Kawai

Hereditary Cancer in Clinical Practice.2021;[Epub] CrossRef

A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model

Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D. N

Biochemical and Biophysical Research Communications.2018; 505(3): 733. CrossRef